Gilead CAR-T cancer therapy capacity to quadruple by 2026

Cell therapies like its chimeric antigen receptor T-cell (CAR-T) treatments Yescarta and Tecartus are increasingly important to Gilead, which has been working for several years to build its presence in oncology and diversify outside of its core HIV business.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/PtDexAN
via